Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
NCT ID: NCT06201650
Last Updated: 2024-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2020-11-11
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis
NCT04455542
Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry
NCT07143656
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
NCT02424669
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
NCT02611674
LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS
NCT07312240
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research objectives comprise:
* Correlation of NfL with disease progression, including duration of ALS disease
* Correlation of NfL with the course of ALS (classic ALS or variants in the motor neuron involvement or the regional propagation patterns)
* Correlation of NfL with the progression rate of ALS
Cohorts on phenotypic variants:
The clinical phenotype of ALS will be differentiated according to the motor neuron involvement or regional propagation patterns of disease onset and clinical course.
ALS variants in relation to motor neuron involvement:
* Typical ALS: clinical features for an affection of the 1st and 2nd motor neurons are present
* Progressive muscular atrophy (PMA): only clinical features for an affection of the 2nd motor neuron are present
* Spastic ALS: predominantly clinical features for an affection of the 1st motor neuron and fewer signs of an affection of the 2nd motor neuron
* Primary lateral sclerosis (PLS): only clinical features for an affection of the 1st motor neuron are present
ALS variants in regional propagation patterns:
* Typical form: paresis of the upper or lower extremities or the bulbar region as well as the spread of the paresis to other regions
* Flail arm syndrome: primary and dominant paresis of the upper extremities and little or delayed spread of the paresis to other regions
* Flail leg syndrome: primary and dominant paresis of the lower extremities and little or delayed spread of the paresis to other regions
* Axial ALS: primary and dominant paresis of the trunk muscles and minor or delayed spread of the paresis to other regions
* Progressive bulbar paralysis: primary and dominant paresis in the bulbar region and slight or delayed spread of the paresis to other regions
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neurofilament light chain
Neurofilament light chain as biomarker for amyotrophic lateral sclerosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient's informed consent to participate in this study
* Minimum age of 18 years
* Willingness for blood collection
Exclusion Criteria
* Evaluation by the investigator, which excludes participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boris Canessa ALS Stiftung
UNKNOWN
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Meyer, MD
Prof. Dr. Thomas Meyer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Meyer, MD
Role: PRINCIPAL_INVESTIGATOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Universität Innsbruck
Innsbruck, , Austria
Vivantes Klinikum Kaulsdorf
Berlin, , Germany
Charité Universitätsmedizin Berlin
Berlin, , Germany
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH
Bochum, , Germany
Universitätsklinikum Bonn
Bonn, , Germany
Technische Universität Dresden
Dresden, , Germany
Alfried Krupp von Bohlen und Halbach Krankenhaus gGmbH
Essen, , Germany
Universitätsklinikum Essen
Essen, , Germany
Georg-August-Universität Göttingen Universitätsmedizin Göttingen
Göttingen, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Universitätsklinikum Jena
Jena, , Germany
Universität Leipzig
Leipzig, , Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, , Germany
Universität Heidelberg Medizinische Fakultät Mannheim
Mannheim, , Germany
Klinikum rechts der Isar der Technischen Universität München
München, , Germany
Westfälische Wilhelms-Universität Münster
Münster, , Germany
Universitätsklinikum Regensburg
Regensburg, , Germany
Universitätsmedizin Rostock
Rostock, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wolfgang Löscher, Prof Dr
Role: primary
Christoph Richter, Dr
Role: primary
Ute Weyen, Dr
Role: primary
Patrick Weydt, PD Dr
Role: primary
René Günther, Dr
Role: primary
Torsten Grehl, Dr
Role: primary
Tim Hagenacker, Prof Dr
Role: primary
Jan Koch, PD Dr
Role: primary
Susanne Petri, Prof Dr
Role: primary
Robert Steinbach, Dr
Role: primary
Petra Baum, PD Dr
Role: primary
Julian Grosskreutz, Prof Dr
Role: primary
Jochen Weishaupt, Prof Dr
Role: primary
Paul Lingor, Prof Dr
Role: primary
Matthias Boentert, PD DR
Role: primary
Zacharias Kohl, PD Dr
Role: primary
Andreas Hermann, Prof. Dr. med. Dr. rer. med.
Role: primary
Johannes Dorst, Prof Dr
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Website of principle investigator
Website of funding organization
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NfL-ALS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.